What do You Think of CPhI? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

What do You Think of CPhI?


CPhI 2012 will draw to a close later today in Madrid. the PharmTech team hope you had a successful show!

Throughout the week, we have been asking what you thought of this year's event. Here is a quick selection are some of the comments we received:

"Very busy show, but very successful and lovely warm weather."

"Crowded, but that's to be expected. Very spread out but meetings have been a success."

"Good foot fall at our stand and great response to our products. The invstment has paid off."

"My first CPhI; very overwhelming and much busier than I expected!"

"It's been successful, as usual for our company, but I'm looking forward to going home."

You can keep up to date with any last minute news and announcements via our Twitter feed @PharmTechGroup.

Or take a look at our archive of CPhI news and announcmenets here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
20%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here